2026 Co-Op, Bacteriology
Description
Moderna's Bacterial Immunology team is seeking a highly motivated Co-op to contribute to the development of new mRNA-based vaccines. This 6-month experiential program, from July 13 to December 11, 2026, offers students currently pursuing an undergraduate or advanced degree in life sciences hands-on experience in genetic characterization of bacterial strains and execution of functional assays within the pharmaceutical and biotechnology industry.
What We're Looking For
Assist in the execution and optimization of bacterial and immunological assays (e.g., antibody binding, ADCD),
Use genetic techniques to investigate key antigen expression in bacterial strains,
Build targeted mutant and/or reporter bacterial strains for assay development,
Independently execute experiments and document scientific work faithfully,
Deliver reproducible and impactful results meeting deadlines,
Analyze, interpret, and present data
Ideal Candidate
Currently enrolled in an undergraduate or graduate program with a focus on Microbiology, Molecular Genetics, Bacteriology, Biology, Molecular Biology, or a related field,
Fundamental knowledge of and experience with wet lab techniques (e.g., pipetting, serial dilution, bacterial growth & aseptic technique, molecular biology techniques like PCR, DNA/RNA extraction, cloning),
Ability to investigate literature for relevant knowledge and protocols,
Legal authorization to work in the US
Minimum Education
Currently pursuing undergraduate or graduate degree in life sciences or related field
Hard Skills
Soft Skills
Work Hours
Full-time during co-op program (July 13 - December 11, 2026)
Benefits
Special Commitments
Legal authorization to work in the US,Must be on-site full-time,Not eligible for remote work,Not eligible for immigration sponsorship,Must hold work authorization in US,Must qualify as a U.S. person (citizens, permanent residents, asylees, or refugees) due to U.S. export control laws (EAR)
About the Company
Moderna, Inc.
Moderna is a biotechnology company pioneering a new class of medicines made of messenger RNA (mRNA). The company's platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.
We respect your privacy
BerryMap uses cookies to provide essential features, analyze usage, and improve your experience. You can customize your preferences below.